527 results about "Target organ" patented technology

This invention overcomes the disadvantages of the prior art by providing a positionable, direct-injection catheters that can access a specific region of the heart or other organ. The catheter is provided with one or two needle shafts, which may be located within respective sheaths that extend axially along the interior of the lumen of a main catheter shaft. Each needle shaft carries, at a distal end thereof a penetrable element or “needle” that is normally retracted within the distal tip of the main shaft during travel to the target organ, but is subsequently deployed by action of a handle-mounted trigger mechanism to extend the needles into the organ's wall. Each extended needle is curved to relative to the shaft's axis to enter the organ wall in a flattened trajectory that both reduces the chance of puncture through the wall and anchors the needles into the wall during injection (for reduced chance of pullout under pressure). A plurality of apertures which provide for more complete agent delivery rapidly, while maintaining a low delivery velocity to effect treatment delivery in as short a period of time as possible without the problems caused by high velocity delivery. The needles are typically arranged to exit the tip at contralateral orientations relative to each other

A method of administering an aerosolized anti-infective, such as a glycopeptide, to the respiratory system of a patient. A ratio of an amount of the glycopeptide, such as vancomycin, delivered to the pulmonary system of the patient in a 24 hour period to a minimum inhibitory amount for the target organ for the same period is about 2 or more. A system to introduce aerosolized medicament to a patient may include a humidifier coupled to an inspiratory limb of a ventilator circuit wye, where the humidifier supplies heated and humidified air to the patient, and an endotracheal tube having a proximal end coupled to a distal end of the ventilator circuit wye. The system may also include a nebulizer coupled to the endotracheal tube, where the nebulizer generates the aerosolized medicament.

Wireless capsule endoscope technology has been used to image portions of the gastrointestinal (GI) tract, particularly the small bowel. However in other GI organs, especially those having larger-lumens, the capsule may become destabilized and tumble, precluding meaningful interpretation of the acquired images. The present invention describes a method and apparatus for permitting capsule imaging of organs having larger-lumens without tumbling, and includes an outer shell surrounding the capsule that targets the colon, as an example. Once the colon has been reached, the shell breaks or dissolves, and allows expansion of expandable materials attached to each end of the capsule, thereby stabilizing the capsule in the targeted organ, while permitting it to be moved by peristalsis and / or other means for locating the capsule. Imagers and light emitting diodes (LEDs) are activated during the expansion process, and enable overlapping of images. The capsule is moved through the colon, taking images at chosen frame rates with data being wirelessly transmitted by means of an RF transmitter, and is eventually expelled from the body.

This invention overcomes the disadvantages of the prior art by providing a positionable, direct-injection catheters that can access a specific region of the heart or other organ. The catheter is provided with one or two needle shafts, which may be located within respective sheaths that extend axially along the interior of the lumen of a main catheter shaft. Each needle shaft carries, at a distal end thereof a penetrable element or “needle” that is normally retracted within the distal tip of the main shaft during travel to the target organ, but is subsequently deployed by action of a handle-mounted trigger mechanism to extend the needles into the organ's wall. Each extended needle is curved to relative to the shaft's axis to enter the organ wall in a flattened trajectory that both reduces the chance of puncture through the wall and anchors the needles into the wall during injection (for reduced chance of pullout under pressure). A plurality of apertures which provide for more complete agent delivery rapidly, while maintaining a low delivery velocity to effect treatment delivery in as short a period of time as possible without the problems caused by high velocity delivery. The needles are typically arranged to exit the tip at contralateral orientations relative to each other.

The present invention includes compositions and methods for delivering one or more active agents in vivo by contacting a target organ or tissue with a microbubble encapsulated active agent comprising a neutrally charged lipid microbubble loaded with cationic liposomes comprising one or more active agents and selectively releasing the active agents at the target by exposing the microbubble at the target with ultrasound, wherein the active agents remain protected in the microbubble until selectively release at the target.

Methods and systems are described for assessing a vessel obstruction. The methods and systems obtain a volumetric image dataset for a target organ that includes a vessel of interest, extract an axial trajectory extending along of a vessel of interest (VOI) within the volumetric image dataset, and create a three-dimensional (3D) multi-planer reformatted (MPR) image based on the volumetric image dataset and the axial trajectory of the VOI. The methods and systems also extract a VOI parameter from the MPR utilizing a machine learning-based vessel obstruction assessment (VOA) model. Methods and systems are also described for implementing a prediction phase to perform at least one of i) detecting plaque type, ii) classifying anatomical severity of vessel blockage, and / or iii) classifying a hemodynamic severity of vessel obstructions within an unseen portion of the volumetric image data set.

A system for segmenting a target organ tumor from an image includes a background model builder, a foreground model builder and a tumor region locator. The background model builder uses an intensity distribution estimate of voxels in an organ region in an image to build a background model. The foreground model builder uses an intensity distribution estimate of voxels in a target organ tumor to build a first foreground model. The tumor region locator uses the background model and the first foreground model to segment the target organ tumor to obtain a first segmentation result.

Methods for treating a patient using therapeutic spinal neuromodulation and associated devices, systems, and methods are disclosed herein. One aspect of the present technology is directed to methods including modulating nerves of one or more targeted organs proximate one or more dorsal root ganglia, stellate ganglia, vertebral ganglia, or cervical ganglia of the nerves using an intravascularly-positioned therapeutic element. One or more measurable physiological parameters corresponding to at least one condition associated with sympathetic activity in the targeted organs and / or central sympathetic activity in the patient can thereby be reduced.

A target positioner including a radiation source disposed in a source housing, the radiation source adapted to emit a radiation beam, a target holder adapted to be attached to and generally immobilize a target organ, the target holder being rotatingly attached to a bearing assembly, a patient support table for supporting a patient thereon, a rotator for turning the patient support table about a rotation axis, and a source arm fixedly attached at one portion thereof to the source housing and at another portion thereof to the bearing assembly, such that when the target holder is attached to a target organ and the rotator turns the patient support table about the rotation axis, the target holder constrains the target organ from translating with respect to the radiation source and the source housing, and wherein the target holder permits the target organ to rotate by means of the bearing assembly relative to the source housing while experiencing slight translations with respect to the patient support table, so that the radiation beam emanating from the radiation source impinges upon the target organ at a plurality of angles irrespective of the misalignments between the radiation beam and the patient support table and between the patient support table and the target organ.

Dry powder formulations of drugs such as antihistamine for nasal administration are provided where the drug is retained in the nasal cavity, and systemic side effects minimized or eliminated, through the selection of a narrow particle size range, between approximately 10 and 20 microns in diameter. In a preferred embodiment wherein the drug is an antihistamine, retention of the antihistamine at the nasal mucosa is improved and the bitter aftertaste associated with liquid antihistamine formulations significantly reduced. By making a dry powder formulation of an antihistamine (e.g., azelastine) having an average particle size of between 10 and 20 microns, the antihistamine is restricted primarily to the desired target organ, the nasal mucosa. Because the active ingredient stays in the nasal region, a lower dose can be used to achieve the same desired effect. As demonstrated by the examples, this lower dose reduces the incidence of somnolence, and because the active ingredient remains at the target organ and does not accumulate in the back of the throat and mouth, this formulation does not impart a bitter taste.

The present invention relates to a medicament comprising a HGF gene. The medicament of the present invention may be topically applied to the target organs so that the effects can be selectively exhibited, resulting in minimizing the side effects of HGF.

Dry powder formulations of drugs such as antihistamine for nasal administration are provided where the drug is retained in the nasal cavity, and systemic side effects minimized or eliminated, through the selection of a narrow particle size range, between approximately 10 and 20 microns in diameter. In a preferred embodiment wherein the drug is an antihistamine, retention of the antihistamine at the nasal mucosa is improved and the bitter aftertaste associated with liquid antihistamine formulations significantly reduced. By making a dry powder formulation of an antihistamine (e.g., azelastine) having an average particle size of between 10 and 20 microns, the antihistamine is restricted primarily to the desired target organ, the nasal mucosa. Because the active ingredient stays in the nasal region, a lower dose can be used to achieve the same desired effect. As demonstrated by the examples, this lower dose reduces the incidence of somnolence, and because the active ingredient remains at the target organ and does not accumulate in the back of the throat and mouth, this formulation does not impart a bitter taste.

Compositions that can include a cationic polymeric carrier, targeting agent, and therapeutic agent are disclosed herein. The therapeutic agent may have a therapeutic activity such as inhibiting fibrosis within a target organ or tissue or inhibiting the growth of a cancer cell.

A radiation therapy dose distribution method starts with selecting a treatment type. Then an organ at risk (OAR) distance to target map is determined. The OAR distance to target map comprises distances to a target organ for portions of an OAR. The OAR distances are determined from at least one segmented patient organ image. A cohort average dose distance to target histogram is selected. A dose value to the portions of the OAR are assigned to form a first 3D dose distribution map. The dose values are from the selected cohort average dose distance to target histogram. A second 3D dose distribution map is determined based on a field arrangement determined by the treatment type and the first 3D dose distribution map. A dose distance to target histogram is calculated using the second 3D dose distribution map and the distance to target map.

The present invention provides methods for enhanced delivery of various therapeutic agents, such as gene therapy agents, to the vasculature of a target organ in a mammalian subject. The methods for targeted gene therapy in the mammalian liver as a whole, or in a single hepatic lobe, are disclosed. The disclosed methods rely on minimally invasive catheter-based procedures wherein a target organ is isolated and treated locally with a gene therapy agent. The methods offer more efficient and localized transfection of tissue and are well-suited for gene therapy in human subjects.